IO Biotech Valuation
| IOBT Stock | USD 0.37 0.02 5.71% |
IO Biotech seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of IO Biotech from inspecting the firm fundamentals such as Gross Profit of (2.59 M), return on asset of -0.89, and Shares Outstanding of 71.95 M as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that IO Biotech's price fluctuation is out of control at this time. Calculation of the real value of IO Biotech is based on 3 months time horizon. Increasing IO Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
IO Biotech's intrinsic value may or may not be the same as its current market price of 0.37, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.37 | Real 0.82 | Hype 0.37 |
The intrinsic value of IO Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence IO Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of IO Biotech helps investors to forecast how IOBT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IO Biotech more accurately as focusing exclusively on IO Biotech's fundamentals will not take into account other important factors: About IO Biotech Valuation
The stock valuation mechanism determines IO Biotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of IO Biotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of IO Biotech. We calculate exposure to IO Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IO Biotech's related companies.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.